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ABSTRACT 
Background. AXL is a membrane receptor tyrosine kinase highly expressed in 
the heart and has a conspicuous role in cardiovascular physiology. The role of AXL in 
heart failure (HF) has not been previously addressed.  
Methods and Results. AXL protein was enhanced 6-fold in myocardial biopsies 
of end-stage HF patients undergoing heart transplantation compared to controls from 
heart donors (P<0.0001). ADAM 10?. Next, we performed a transversal study of 
patients with chronic HF (n=192) and a group of controls with no HF (n=67). sAXL and 
BNP circulating levels were quantified and clinical and demographic data were 
collected.  
sAXL levels in serum were higher in HF (86.3±2.0 ng/mL) than in controls (67.8±2.0 
ng/mL; P<0.0001). Also, sAXL correlated with several parameters associated with 
worse prognosis in HF. Linear regression analysis indicated that serum creatinine, 
systolic blood pressure and atrial fibrillation, but not BNP levels, were predictive of 
sAXL levels. Cox regression analysis indicated that high sAXL values at enrollment 
time were related to the major HF events (all-cause mortality, heart transplantation and 
HF hospitalizations) at one year follow-up (P<0.001), adding predictive value to high 
BNP levels.  
Conclusions. Myocardial expression and serum concentration of AXL is 
elevated in HF patients compared to controls. Furthermore, peripheral sAXL correlates 
with parameters associated with the progression of HF and with HF events at short term 
follow-up. All together these results suggest that sAXL could belong to a new 
molecular pathway involved in myocardial damage in HF, independent from BNP. 
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Introduction 
Heart Failure (HF), characterized by a ventricular systolic or diastolic 
dysfunction, constitutes the end-stage of many heart diseases. Population prevalence of 
HF averages 2 to 3% increasing to ≥10% at 70 years of age or older.(1, 2) 
Epidemiological studies report a link between HF and low survival rates.(3) Several 
etiologies underlie the diagnosis of HF, including pathological remodeling of the 
myocardium after an infarct. Other important etiologies include cardiomyopathies, 
hypertension, valvular heart disease, and toxins. Therefore, we can consider HF as a 
multifactorial syndrome with abnormalities of cell signaling, that are reflected in the 
contractile function of the myocardium as well as in cardiac cell survival and death. (4, 
5) 
Receptor tyrosine kinases (RTKs) are membrane proteins recognizing 
extracellular signals leading to cellular responses such as proliferation, arrest or 
activation. AXL belongs to the Tyro3, Axl and MerTK (TAM) subfamily, of RTKs and 
is a protein of particular interest as a potential player in the pathophysiology of the 
failing heart. Although the TAM receptors were first cloned as orphan receptors, affinity 
purification techniques led to the identification of Growth Arrest-Specific 6 protein 
(GAS6) as the AXL ligand.(6) GAS6 has significant structure and sequence similarity 
with the vitamin K-dependent protein S, but lacks its anticoagulant activity.(7) Cells of 
the vasculature including endothelial cells, vascular smooth muscle cells and fibroblasts 
synthesize and express GAS6 and AXL.(8, 9) According to the GeneAtlas data set, 
AXL is highly expressed in the heart, including cardiomyocytes, among other 
organs.(10) Membrane bound AXL can be shed by the effects of a Disintegrin and 
Metalloproteinase domain-containing protease (ADAM), ADAM10? leading to a 
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soluble form that is detected in plasma as a stable complex with its ligand GAS6.(11, 
12)  
 The aim of this project was to analyze the AXL myocardial and serum levels in 
patients with HF and whether it could be useful in assessing the stage of the HF. Hence, 
we analyzed the relationship of sAXL with parameters that are affected in HF and 
estimated the value of sAXL in predicting events at one year follow-up. 
 
Methods 
Collection and analysis of human heart samples 
Human heart samples were analyzed in 2 populations: control samples (n=11) 
were non-diseased biopsies. These samples were from organ donors whose heart could 
not be used for transplantation because they did not match the requirements of the 
potential heart receptors. Left ventricle samples were collected at the time of organ 
donation. 
Case samples (n=15) were pathological human left ventricle biopsies from 
patients with severe HF obtained at the time of cardiac transplantation, as described 
previously.(13) Whenever it was possible, sample harvest of around 1 cm
3
 myocardial 
biopsies was performed in a middle region between the apex and the base. The 
myocardial tissue was immediately immersed in liquid nitrogen. The Ethical Committee 
of the affiliated institution approved the protocol. 
 
Western Blot analysis of sAXL protein 
Myocardial proteins were extracted from left ventricle biopsies, if possible from 
the anterior wall. Samples were submerged in 1 mL of ice-cold protein lysis buffer 
containing: 50 mM Tris HCl pH 7.5 (T5941, Sigma), 150 mM NaCl (1.06404.5000, 
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Merck), 1% Nonidet P-40 (Tergitol solution, NP40S, Sigma), 0.5% sodium 
deoxycholate (D6750, Sigma),  0.1% sodium dodecyl sulfate (L5750, Sigma), 1 mM 
phenylmethanesulfonyl fluoride (P7626, Sigma), 1 mM sodium orthovanadate (S6508, 
Sigma), 1 mM Pefabloc (11429868001, Roche) and complete Mini Protease Inhibitor 
Cocktail (11836153001, Roche). Samples were homogenized with an Omni TH 
homogenizer (Omni International Inc.). After 1 hour of rotation at 4 ºC, samples were 
centrifuged at 10.000 g at 4 ºC for 30 minutes. The upper phase was collected and the 
total protein concentration was quantified with the Pierce BCA protein Assay method 
(23227, Thermo Scientific, Pierce) relative to a BSA standard curve. Thirty g of total 
protein extract were loaded to NuPage® 4–12% Bis-Tris Gel (NP0322) and a western 
blot was performed with the Novex® gels methodology (Invitrogen). Proteins were 
transferred from the gel to a nitrocellulose membrane using a blot gel transfer (IB3010-
01) and the iBlot® Dry Blotting System. After 1 hour blockade of the membrane with 
phosphate buffered saline solution (PBS, Fisher Scientific), 0.1% Tween 20 (P1379, 
Sigma-Aldrich) and 5% of skimmed milk,  it was incubated overnight at 4 C with the 
AXL (c-20) primary antibody against the carboxy terminal protein of the full-length 
human protein diluted 1/1000 (sc-1096, Santa Cruz Biotechnology). Afterwards, the 
membrane was incubated during 1 hour with an HRP-Rabbit anti-Goat secondary 
antibody diluted 1/5000 (31402 Thermo Scientific). Final detection of the AXL protein 
band was accomplished with the ECL kit Supersignal West Pico Chemioluminescent 
Substrate (34080, Thermo Scientific).  
Quantification of the integrated density of the bands around 150 kDa was done 
with the ImageJ program (NIH, Maryland, USA). Each blot was loaded with 30 g of a 
standard sample of human myocardial protein for calibration between blots. Results are 
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given in relative units (RU) as the ratio between the integrated densities of each sample 
divided by the integrated density of the standard.. ADAM10?  
 
Patient enrolment and collection of clinical data  
This was a transversal study of patients treated in a specialized outpatient HF 
clinic with chronic, stable HF with systolic dysfunction, characterized by an ejection 
fraction (EF) less or equal to 40% (mean evolution HF time of 7.5±0.6 years). 
Participants were recruited in a consecutive manner based on presenting the inclusion 
criteria from May 2009 to November 2011 in the Hospital Clinic of Barcelona and from 
November 2010 to October 2011 in the Hospital Sant Pau of Barcelona. Patients 
belonged to New York Heart Association (NYHA) functional classes II, III or IV 
(mainly II and III). HF patients were diagnosed and assigned to a NYHA class by a 
group of cardiologists specialized in heart failure and heart transplantation according to 
the European Society of Cardiology criteria.(2) These patients were considered to have 
stable HF because they did not have a hospital admission with a diagnosis of HF during 
the previous month before enrolment.  
  Historical records from these patients were retrieved and an echocardiography 
taken within a year from the inclusion day was used for each patient. Clinical data such 
as ECG data, HF evolution time, functional capacity measured as 6-minute walking test 
(6MWT), cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus and 
smoking), laboratory parameters and medication were entered for analysis. Ventricular 
dilation parameters, systolic function and the EF were assessed by echocardiography. 
One hundred ninety-two patients were included with a major reduced left ventricular 
function, and were designated as HF. Patients under 18 years of age were excluded as 
well as patients affected by other fibroproliferative diseases such as; kidney failure 
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(creatinine levels> 3 mg/dL), cirrhosis, bone metabolic disease, hyperthyroidism, 
pulmonary fibrosis, systemic sclerosis, macular degeneration and amyloidosis. 
This study complies with the Declaration of Helsinki, the Ethical Committee of 
the affiliated institution approved the protocol and all subjects gave written, informed 
consent to participate in this study. 
 
Patient short term follow-up 
Follow-up data of one year +/- 1 month were obtained from either a clinical or a 
telephone interview or from the clinical records. The events that were recorded were as 
follows: hospitalizations for either HF, acute coronary syndrome, cardiorespiratory 
arrest, ventricular tachycardia or fibrillation; device implantation of either a pacemaker, 
an implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy (CRT 
with or without ICD); percutaneous revascularization; cardiac surgery (for either heart 
transplantation, coronary revascularization or others); ictus and all-cause mortality 
(cardiac and non-cardiac deaths).  
 
Controls characteristics 
Controls were a group of subjects with no HF with a lower proportion of male 
subjects (46%) than the patients (85%, P<0.0001). Controls mean age was 48.6±2.0 
years (n=67) and was lower than the mean age of the patients 61.8±0.8 years (n=192, 
P<0.0001). HF patients had higher proportions of all risk factors than controls; 
Hypertension P<0.0001, Dyslipidemia P<0.0001, Diabetes Mellitus P<0.01, 
Current/former smoker P<0.0001, Previous AMI P<0.0001. 
 
Collection and analysis of serum and plasma samples  
9 
 
Blood samples were collected from an antecubital vein from all HF patients and 
controls. Serum and plasma samples from the HF patients were collected on the 
enrolment day. 
To measure circulating levels of BNP, whole blood was collected in a chilled 
tube with the anticoagulant EDTA.(14) The sample was promptly put on ice after blood 
extraction and was centrifuged at RCF 1800 g for 10 minutes at 4 ºC. The supernatant 
was collected, aliquoted and kept at –80 ºC until analysis. Quantification of BNP 
plasma levels was performed and validated in the Biomedical Core Facility of the 
Hospital Clínic of Barcelona. Briefly, plasma BNP was quantified with a 
chemiluminometric immunoassay run on the ADVIA Centaur Immunochemistry 
analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). The intra-assay 
coefficient of variation was of 1.8-4.3 % CV and the inter-assay coefficient of variation 
was of 2.3-4.7 % CV.   
Serum samples for sAXL analysis were kept at room temperature for at least 30 
minutes after blood extraction, to let the clot to be formed and were later centrifuged at 
RCF 1800 g for 10 minutes at room temperature. The supernatant was collected, 
aliquoted and kept at –80 ºC until analysis. A new detection method for sAXL 
quantification was devised in our laboratory using commercially available antibodies. 
Multiwell plates (96 wells, Rubilabor) were coated with the capture antibodies AF154 
(R&D Systems) at a concentration of 2.0 g/mL in PBS (137 mM NaCl, 2.7 mM KCl, 
8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2, filtered through a 0.2 m pore). The plates 
were sealed and left overnight at room temperature. The plates were washed three times 
with wash buffer (PBS with 0.05% Tween20) and then were blocked for 1 hour at room 
temperature with PBS containing 1% BSA (Sigma). Serum samples were diluted 200 
times in PBS containing 1% BSA. A standard curve was made by serial dilution of a 
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purified sAXL protein produced by recombinant expression of the extracellular part of 
AXL (R&D Systems) and concentrations are given as ng/mL. A negative control 
without plasma sample was used and pooled-plasma samples were used in each plate as 
plate controls. After sample addition, the plates were washed three times with wash 
buffer (PBS with 0.05% Tween20). Then, 100 L of the BAF154, diluted in PBS 
containing 1% BSA was added at a concentration of 50 ng/mL and incubated 2 hours at 
room temperature. The aspiration/wash steps were repeated and 100 L of the working 
dilution of Streptavidin-HRP (Sigma) were added to each well. The plate was covered 
and incubated for 20 minutes at room temperature. The aspiration/wash steps were 
repeated and a solution of tetramethyl-benzidine (slow kinetic form; Sigma) was added 
to the well. The reaction was stopped with sulfuric acid at 1 M concentration. The 
absorbance of wells was determined with an automatic plate reader at 450 nm. Intra-
assay variability was determined by evaluating eight replicates of two standard samples. 
The mean %CVs was 6.45 and 9.21, respectively. Inter-assay mean %CV was 
determined in six different plates and gave the value of 8.32. 
 
Data analysis 
Logarithmic transformation with base e (ln) was applied to sAXL and BNP 
values to achieve a normal distribution. Ln(sAXL) and Ln(BNP) were back transformed 
and results are discussed in the text with the original sAXL and BNP values. The 
independent samples T-test was applied to analyze for ln(sAXL) differences between 
the control and the patients groups or between two groups of patients. Patients were 
stratified as patients with low sAXL levels (L-sAXL; sAXL values below the 3
rd
 
quartile 98.1 ng/mL) or high sAXL (H-sAXL; sAXL values equal or above the 3
rd
 
quartile 98.1 ng/mL). Differences in continuous variables between both groups were 
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assessed with a U Mann-Whitney test and differences in discontinuous variables with a 
Chi-Square test. Values are given as mean and standard error of the mean (SEM), unless 
otherwise stated. We analyzed whether the continuous variables that had different mean 
values in the two HF groups with L-sAXL<98.1 ng/mL or H-sAXL ≥98.1 ng/mL (Table 
1 and Table 2), correlated with ln(sAXL) serum values with the Pearson correlation 
factor. The variables that were considered for a putative correlation with ln(sAXL) 
serum values were: systolic blood pressure, diastolic blood pressure, 6-minutes walk 
distance, serum creatinine levels, glomerular filtration rate, C reactive protein, uric acid, 
hemoglobin, hematocrit and hematies and lymphocyte count. We also assessed whether 
there was a correlation between the sAXL serum values and the established HF 
biomarker BNP. All variables correlated with ln(sAXL) serum values and were 
introduced in the linear regression model as independent variables and ln(sAXL) serum 
levels as the dependant variable. ENTER and STEPWISE methods were both used for 
introducing the independent variables. 
The relationship between ln(sAXL) and the non-continuous variables that were 
different between the two HF groups (sAXL<98.1  ng/mL or sAXL ≥98.1  ng/mL, was 
evaluated by an unianova analysis. The variables valvular etiology and congestion signs 
did not present statistical differences in the unianova analysis and were not further 
studied. The variables dyslipidemia, NYHA classification and atrial fibrillation showed 
differences with the unianova analysis and were introduced in the linear regression 
model together with the continuous variables serum creatinine levels and systolic blood 
pressure. Receiver-Operator Characteristic Curve (ROC) analysis of sAXL for 
discriminating HF patients from controls was performed. The cut-off value for 
calculation of the specificity and sensitivity was the nearest point to the upper-left 
corner and the point with highest Youden’s index value. 
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HF evolution measured by time to any event or to the set of events all-cause mortality, 
heart transplantation and hospitalizations due to HF was analysed using statistical 
survival techniques. The 3
rd
 quartile value of the sAXL distribution (98.1 ng/mL) or of 
the BNP distribution (362.7 pg/mL) were used as cut-off points for stratification in the 
Kaplan-Meier survival curves, and patients were divided in three groups with sAXL 
above the 3
rd
 quartile, with BNP above the 3
rd
 quartile or with both, sAXL and BNP, 
above the 3
rd
 quartile. Patients lost at the follow-up (10 out of 192) were not included in 
the analysis. Univariate Cox regression model was evaluated with either all events or 
with the three HF events; all-cause mortality, heart transplantation or HF hospitalization 
or with only the two major events all-cause mortality, heart transplantation as outcomes. 
Hazard ratios were also calculated with the Cox proportional hazard analysis.  A Cox 
regression analysis with a forward stepwise model was performed to verify whether the 
variable of sAXL values belonging to the 3
rd
 quartile added prognostic value to the 
evaluation of patients with BNP levels belonging to the 3
rd
 quartile. 
All P values reported are 2 sided, and those that were less than 0.05 were considered to 
be statistically significant. Statistics were calculated with the SPSS version 18.0 (SPSS 
Inc. Chicago, Illinois).  
 
Results 
AXL protein is higher in myocardial samples from end-stage HF patients than in 
controls  
Western blot analysis of myocardial biopsies from 26 individuals showed the 
presence of AXL as two high molecular weight bands of approximately 160, 140 kDa 
(Figure 1A), and three other bands of lower molecular weight (120, 75 and 50 kDa), 
possibly corresponding to proteolytic fragments or splicing variants of the full length 
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membrane receptor. The upper 160 and 140 kDa bands were quantified by densitometry 
and compared, showing that samples from 15 HF patients undergoing heart 
transplantation had a 6-fold increase in AXL immunoreactivity compared to 11 control 
donors with healthy hearts (1.2±0.2 Relative Units (RU) versus 0.2±0.5 RU; P<0.0001, 
Figure 1B). ADAM10? Correlació AXL I ADAM10?  
 
sAXL is higher in HF patients than in controls and correlates with parameters 
associated with the progression of HF 
sAXL levels in serum were higher in patients 86.3±2.0 ng/mL than in controls 
67.8±2.0 ng/mL (P<0.0001, Figure 2A). Higher sAXL values were also encountered in 
patients with NYHA class III-IV 100.2±4.9 ng/mL (n=54) compared to class II patients 
80.9±1.9 ng/ml (n=138; P=0.0001, Figure 2B). Similar sAXL values were found in HF 
patients with different etiologies, with the exception of higher values in patients with 
valvular etiology, when compared against all other HF patients (table 1 and Figure 3).  
Receiver-Operator Characteristic Curve (ROC) analysis of sAXL for 
discriminating HF patients from controls was performed. The area under the curve 
(AUC) was 0.715 and its 95% confidence interval estimate was from 0.649 to 0.782 
(P<0.0001). A cut-off point value of 71 ng/ml of sAXL gave a 70.3% of sensitivity and 
64.2% of specificity. 
 
Patients’ characteristics  
        Comparison of the demographic and clinical characteristics of HF patients 
classified as patients with serum sAXL levels lower than 98.1 ng/mL, the 3
rd
 quartile 
value of sAXL (L-sAXL, n=144) or patients with higher or equal serum sAXL levels 
than 98.1 ng/mL (H-sAXL, n=48) is summarized in Tables 1 to 4. Lower systolic 
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arterial pressure (P<0.005) and lower diastolic arterial pressure (P<0.01) and less 
functional capacity measured with the 6-minutes walk test (P<0.05) were found in the 
H-sAXL group when compared to the L-sAXL group (Table 1). Among common 
cardiovascular risk factors, lower proportion of dyslipidemia were found in the H-sAXL 
than in the L-sAXL group (P<0.005, Table 1). When comparing the frequency of 
symptoms and signs between both groups, we found a higher proportion of patients with 
congestion signs, in the H-sAXL than in the L-sAXL group (P<0.01, Table 2). 
         No differences in the echocardiographic characteristics were found between both 
groups of HF (Table 2). When comparing ECG findings, we encountered that the H-
sAXL group had a higher percentage of patients with atrial fibrillation than the L-sAXL 
group (P<0.05, Table 2). Patients in the H-sAXL group had higher values of BNP 
(P=0.001), serum creatinine (P<0.001), lower glomerular filtration rate (P<0.0001), 
higher uric acid levels (P<0.05) and higher C Reactive Protein (P<0.01, Table 3). 
Analysis of blood parameters showed that the H-sAXL group had lower lymphocytes 
(P<0.05) and erythrocyte count (P=0.001), hemoglobin levels (P<0.05) and hematocrit 
(P<0.05, Table 3). No other differences in laboratory values were found between the 
two subsets of patients. Pharmacological treatment was very similar in both groups 
except for a lower intake of statins in the H-sAXL group (P<0.01, Table 4) and for a 
higher proportion of patients taking diuretics, oral digoxin and antiarrhytmics in this 
group that almost reached significant differences. 
 
Analysis of sAXL with other clinical variables  
 
We next analyzed whether the continuous variables that had different mean 
values in the two HF groups with L-sAXL<98.1 ng/mL or H-sAXL ≥98.1 ng/mL 
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(Tables 1 to 3), correlated with ln(sAXL) serum values with the Pearson correlation 
factor. We found that ln(sAXL) serum values directly correlated with ln(BNP) 
(R=0.270, P<0.001, n=167) serum creatinine levels (R=0.36, P<0.0001, n=189), C 
reactive protein (R=0.227, P<0.01, n=143), uric acid (R=0.253, P<0.01, n=132) and 
inversely with systolic blood pressure (R=-0.323, P<0.0001, n=184) diastolic blood 
pressure (R=-0.238, P=0.001, n=183), 6-minutes walk distance (R=-0.207, P<0.01, 
n=171), glomerular filtration rate (R=-0.296, P<0.0001, n=178), hemoglobin (R=-0.217, 
P<0.01, n=187), hematocrit (R=-0.207, P<0.01, n=189), hematies count (R=-0.243, 
P<0.01, n=183) and lymphocytes count (R=-0.211, P<0.01, n=188) . 
Evaluation of the putative interaction between ln(sAXL) and the continuous 
variables that correlated with ln(sAXL) was done with a linear regression method with 
ln(sAXL) as a dependant variable. We found that serum creatinine levels (P<0.0001) 
and systolic blood pressure (P<0.001) were predictive of ln(sAXL) serum levels. And 
all other continuous variables, including BNP, were not predictive. When we introduced 
non-continuous variables in the linear regression model atrial fibrillation was predictive 
of ln(sAXL) (P<0.001) together with serum creatinine levels and systolic blood 
pressure. 
We also analyzed whether sAXL levels correlated with variables such as age, 
gender, and risk factors in controls. Higher sAXL values were quantified in female 
controls (73.2 ± 3.5 ng/mL, n=36) than in male controls (64.5 ± 3.3 ng/mL, n=31,) but 
the difference was not statistically different. No differences of sAXL levels were found 
with controls age, and common cardiovascular risk factors (data not shown). 
 
Analysis of sAXL in one year follow-up events 
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At one year +/- 1 month after enrollment 52 patients out of 182 (29%) had had at least 
one event of any kind and the remaining 130 patients did not have any event (71%). 
When considering only major HF events (all-cause mortality, cardiac transplantation or 
HF hospitalizations), 33 patients had an event (18%) and 149 (82%) did not have any 
HF event. Kaplan-Meier survival curves and Cox regression analysis showed time 
course differences in patients that suffered from major HF events between patients with 
sAXL values lower or higher than the cut-off point of the 3
rd
 quartile 98.1 ng/mL 
(P<0.001, figure 4A). A 35% of patients with sAXL values higher than 98.1 ng/mL had 
suffered one of these events one year after enrollment, and their hazard ratio (HR) was 
3.31. Such differences were also observed between patients with BNP values lower or 
higher than the cut-off point of the 3
rd
 quartile 362.7 pg/mL (P<0.0001, figure 4B). A 
total of 42% of patients with BNP values higher than 362.7 pg/mL presented a major 
HF event at one year follow-up, and the HR of these patients was 4.4. When we 
classified patients with a combination of both, sAXL and BNP, values above the 3
rd
 
quartile or not, we found higher differences in the Cox regression model (P<0.0001, 
figure 4B) than when considering sAXL or BNP values alone. In this case, the 
percentage of patients in the high sAXL and BNP group that had undergone all-cause 
mortality, transplantation or HF hospitalizations rose to 62% and the HR to 6.77. 
Furthermore, a Cox regression analysis with a forward stepwise model showed that the 
addition of the variable of patients belonging to the sAXL 3
rd
 quartile added prognostic 
value for major HF events to the variable of patients belonging to the BNP 3
rd
 quartile 
(p<0.05).  
Remarkably, when considering only the major events all-cause mortality and 
heart transplantation, Kaplan-Meier curves and Cox regression analysis with patients 
with high sAXL also showed differences when compared to patients with low sAXL 
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values (P<0.001, HR=4.40). Those differences were also found when analyzing patients 
according to their BNP levels (P<0.001, HR=5.14) and were higher when comparing 
patients with both high sAXL and BNP levels and the rest (P<0.0001, HR=8.54). 
Kaplan-Meier curves and Cox regression analysis considering all types of events 
together also presented differences between patients with high and low sAXL (P<0.05, 
HR=1.85) but the differences were less than when considering only the major HF events 
or only all-cause mortality and heart transplantation. The survival curves with all events 
were also different for patients with BNP values above the 3
rd
 quartile (P<0.001, 
HR=3.04) or with both BNP and sAXL values above the 3
rd
 quartile (P<0.001, 
HR=4.13). 
 
Discussion 
In this report we demonstrate for the first time that AXL is expressed in the heart 
and that is increased in myocardial tissue from HF patients compared to healthy hearts 
and, in accordance with this over-expression, the serum concentration of sAXL is 
higher in HF patients than in controls. Furthermore, sAXL levels increase in aggravated 
HF, in patients with functional class III-IV and with multiple clinical parameters that 
indicate a worse HF prognosis but no correlation with echocardiographic parameters 
was found. Also, linear regression analysis showed that BNP levels did not predict 
sAXL levels, suggesting that both proteins are elevated through independent 
mechanisms. 
High sAXL values at the enrollment time were related to the HF events all-cause 
mortality, transplantation or HF hospitalizations at one year follow-up and it added 
predictive value to high BNP levels. All together these results, suggest that sAXL can 
be a novel player of the HF pathophysiology, acting in a BNP independent pathway.  
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The detection of AXL protein in myocardial biopsies confirms results in silico 
that showed a relatively high expression of AXL probes in heart and cardiomyocytes 
(Gene atlas, human probe 202686_s_at).(10) Moreover, it suggests that at least part of 
the soluble receptor detected in serum could be originated in heart after specific 
proteolytic shedding, as has been shown in other cell types.(12) ADAM10? 
Currently, we do not know the role of AXL in HF and whether its expression is 
deleterious for the heart or if it is a compensatory mechanism. The GAS6/AXL 
interaction has demonstrated a prominent role in vascular physiology, including 
biological processes implicated in HF such as inflammation, tissue remodeling, vascular 
calcification and atherosclerosis.(15, 16) Tjwa et al(17) showed that GAS6 facilitates 
the interactions between endothelial cells, platelets, and leukocytes under inflammatory 
conditions. This mechanism is likely mediated by AXL, as AXL knockout mice present 
lower extravasated cells after vascular injury.(18) AXL also appears to have an 
important role in the vascular response to different injuries, including mechanical 
damage and hypertension-associated vascular remodeling.(18-21) A third process where 
AXL plays a prominent role is vascular calcification. AXL activation prevents the 
osteogenic differentiation of pericytes and vascular smooth muscle phosphate induced 
calcification.(22, 23) In addition, Son et al described the GAS6/AXL pathway as a 
central interface for the protective effects of statins on vascular smooth muscle 
calcification.(24) Finally, AXL has also been found to have a role in atherosclerosis.(8, 
9) Our results showed correlation of sAXL levels with the inflammatory parameter C-
reactive protein (CRP) (25) in HF patients. On the other hand, we find a higher 
proportion of dyslipidemia in patients with lower values of sAXL, which would not 
sustain a role of AXL in the atherosclerosis process in this group of patients with HF. 
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Experimentation with animal models is needed in order to ascertain whether there is a 
causative relation of AXL and any of these pathways in HF. 
The lack of correlation of sAXL circulating levels and echocardiographic 
parameters, such as LVEDD, LVESD and LVEF, suggests that AXL shedding into 
blood follows different triggering signals than BNP. Natriuretic peptides are shed from 
the heart when there is an overload on any chamber of the heart, and hence there is a 
stretch situation (26, 27). It should be emphasized that even though lnBNP and lnsAXL 
values correlate; BNP does not appear to be a predictor of sAXL levels in a linear 
regression model. 
 Circulating sAXL in patients and controls correlates with several parameters 
that are altered in HF and that lead to a worse prognosis. In our results, higher sAXL 
levels are found in HF patients with more functional limitation determined either by the 
NYHA classification or by the formal 6MWT of exercise tolerance.(28, 29) Also, HF 
patients with higher peripheral sAXL levels presented lower systolic and diastolic blood 
pressure. Low arterial pressure will compromise critical organ perfusion and is 
associated with a poorer prognosis.(30) Furthermore, we quantified increased serum 
sAXL levels together with increased kidney dysfunction determined by either higher 
serum creatinine levels or by lower glomerular filtration rates. Indeed, the GAS6/AXL 
pathway has been shown to be implicated in development of several renal 
pathologies.(31, 32) Also, HF patients in the H-sAXL group had higher uric acid levels 
and sAXL was highly correlated with bilirubin and anemia in HF patients, three 
parameters that are associated with adverse outcomes in HF.(33-35)  
Our ROC analysis of sAXL for discriminating HF patients from controls, shows 
that sAXL as a putative diagnostic marker has much less sensitivity and specificity than 
BNP (data not shown). In the acute setting, testing for the natriuretic biomarkers to rule 
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out or to confirm the HF diagnosis is well established(28, 36, 37) and are indicated in 
Clinical Guidelines.(2, 29, 38) The natriuretic peptides are also well established HF 
prognostic markers. The higher rate of HF events we find in this group of HF patients 
with reduced ejection fraction and high BNP levels is in accordance with other results in 
the literature that have shown that the natriuretic peptides are powerful predictors of 
adverse outcomes in patients with HF(39-44). 
Other biomarkers such as cardiac necrosis markers, troponin I or T, (45, 46) or 
fibrosis markers such as soluble ST2 (47-49) and galectin-3 (50, 51)  have been shown 
to be predictive of hospitalization and death in patients with HF and have an additive 
prognostic value to natriuretic peptide levels. The carbohydrate antigen 125 (CA125) 
also has a predictive value of adverse outcomes in HF patients (52) and adds prognostic 
value to BNP (53). Our results indicate that sAXL is also predictive of HF events at 
short-term follow-up and that the combination of an elevated sAXL with BNP was a 
better predictor of major HF events and of all-cause mortality and heart transplantation 
than either of the two markers alone.  
The fact that AXL is 6-fold over expressed in pathological ventricular heart 
biopsies, suggests that the increased levels encountered in the peripheral blood samples 
from HF patients is shed from the heart.  
 
Conclusions 
Altogether, we have presented in this report quantification of AXL in heart 
biopsies by western blot and of sAXL in serum by a new enzyme-linked 
immunosorbent assay (ELISA). sAXL levels in HF correlate with BNP levels, the 
current marker of HF and with other clinical parameters related to aggravated HF. 
Remarkably, high sAXL levels predicted HF events at short term follow-up, and added 
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predictive value to BNP. Based on these results, we conclude that sAXL appears to 
have a role in HF progression in a distinct molecular pathway than BNP. 
 
Study limitations 
The control group of the sAXL serum analysis was not matched with the HF 
group in age and cardiovascular risk factors. This is a serious limitation of this study, but 
analysis of sAXL levels in the control group indicated that was independent of the 
subject’s age and sex. On the other hand, the difficulty of finding controls with several 
cardiovascular risk factors and no cardiovascular disease precluded the obtention of such 
samples.  
This is a two center study from the same metropolitan area, with consecutive 
patients enrolled. And although it has some advantages, such as including a more 
homogeneous diagnosis, demographics and laboratory techniques, validation of these 
results in other centers or in multicentric studies will be needed to confirm the increase of 
sAXL in HF patients from other populations. 
We were not able to obtain the cause of mortality from the records in most of the 
cases. Therefore, we have analyzed the variable all-cause mortality and could not do 
analysis with only cardiovascular causes of mortality.  
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Table 1. Baseline demographic, prior history and clinical characteristics of HF 
patients stratified by sAXL 3
rd
 quartile level. 
______________________________________________________________________ 
            sAXL, ng/mL   
      ___________________________________ 
Parameter      <98.1  ≥98.1  P 
No of patients          144  48 
___________________________________________________________________ 
Demographics 
Age, y,     61±1  64±1  ns 
Male, n (%)     123 (85) 41 (85) ns 
Female, n (%)     21 (15) 7 (15)  ns 
Risk Factors, n (%) 
 Hypertension     109 (77) 34 (72) ns 
Dyslipidemia     95 (68) 20 (44) <0.005 
Diabetes Mellitus     50 (35) 16 (33) ns 
Current/former smoker   104 (73)          28 (61) ns 
Previous AMI     70 (50) 20 (44) ns 
Clinical characteristics 
Body Mass Index, Kg/m2   28.1±0.4 27.9±0.8 ns 
NYHA classification, n (%) 
II     112 (78) 26 (54) <0.005 
III-IV     32 (22) 22 (46) <0.005 
 Etiology, n (%) 
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  Idiopathic    40 (28) 13 (27) ns 
  Ischemic    75 (52) 18 (38) ns 
  Valvular    12 (8)  11 (23) =0.01 
  Hypertensive    4 (3)  1 (2)  ns 
  Other     13 (9)  5 (10)  ns 
 Heart rate, beats/min    71.5±1.2 72.2±2.1 ns 
 Systolic blood pressure, mm Hg  120.0±1.9 108.9±2.4      <0.005 
 Diastolic blood pressure, mm Hg  73.3±1.0 68.3±1.5        <0.01 
Pulse pressure     47.1±1.6 40. 6±2.2 ns 
Abdominal perimeter, cm   102.8±1.2 103.9±3.1 ns 
6-min walk distance, m   418±8.9 372±17.4 <0.05 
______________________________________________________________________ 
AMI (acute myocardial infarction) 
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Table 2. Baseline HF symptoms and signs, ECG and echocardiographic 
parameters of HF-REF patients stratified by sAXL levels. 
______________________________________________________________________ 
               sAXL, ng/mL 
      ___________________________________ 
Parameter      <98.1  ≥98.1  P 
No of patients          144  48 
______________________________________________________________________ 
Symptoms and signs 
         Paroxysmal nocturnal dyspnea, n (%)  24 (18) 6 (15)  ns 
         Reduction in exercise tolerance, n (%)  56 (42) 18 (50) ns 
         Orthopnea, n (%)    40 (30) 11 (28) ns 
         Syncope, n (%)      19 (14) 4 (9)  ns 
         Lower extremity edema, n (%)    18 (13) 6 (14)  ns 
         Congestion signs, n (%)     4 (5)  6 (27)  <0.01 
         Jugular venous distension, n (%)     7 (9)  5 (24)  ns 
         Hepatojugular reflux, n (%)     14 (18) 4 (20)  ns 
ECG parameters  
Sinusal Rhythm, n (%)     86 (61) 24 (52) ns 
Atrial Fibrillation, n (%)     9 (6)  8 (17)  <0.05 
QRS length, ms    134.8±3.2  134.5±5.5  ns 
Interval PR, ms    168.9±4.0  168.6±6.0  ns 
Necrosis Q waves, n (%)       32 (34) 7 (24)  ns 
Intervent conduct disorders, n (%)  77 (61)  28 (70) ns 
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Left bundle branch block, n (%)  18 (21) 8 (29)  ns 
Pacemaker, n (%)    77 (54) 29 (60) ns 
Resynchronization therapy, n (%)  19 (13) 4 (8)  ns 
Echocardiographic parameters 
 LVESD, mm     53.5±1.0 53.6±1.7 ns 
 LVEDD, mm     67.5±0.8 66.9±1.2 ns 
 LVEF, %     27.6±0.6 26.5±1.0 ns 
LAD, mm     47.4±0.7 50.5±1.6 ns 
IVST, mm     10.3±0.1 10.8±0.3 ns 
 LVPWT, mm     9.9±0.1 10.1±0.2 ns 
LVH, n (%)      57 (42) 24 (53) ns 
______________________________________________________________________ 
Intervent conduct disorders (Interventricular conduction disorders), LVESD (left 
ventricle end-systolic diameter), LVEDD (left ventricle end-diastolic diameter), LVEF 
(left ventricle ejection fraction), LAD (Left atrial diameter), IVST (Interventricular 
septum thickness), LVPWT (Left ventricular posterior wall thickness), LVH (Left 
Ventricular Hypertrophy defined as IVST≥11mm). 
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Table 3. Baseline laboratory values of HF patients stratified by sAXL levels. 
______________________________________________________________________ 
            sAXL, ng/mL 
      ___________________________________ 
Parameter      <98.1  ≥98.1          P  
No of patients          144  48 
______________________________________________________________________ 
BNP, pg/mL            251.9±37.1    456.6±69.2   =0.001 
Serum creatinine, mg/dL    1.12±0.03  1.36±0.07     <0.001 
Glomerular filtration rate, mL/min   57.9±0.7 52.2±1.7        <0.0001 
Sodium, mEq/L     140.0±0.3 139.3±0.6     ns 
Potassium, mEq/L     4.6±0.04 4.5±0.09       ns 
Aspartate Aminotransferase, UI/L   24.4±0.7  31.9±5.7       ns 
Alanine Aminotransferase, U/L   25.6±1.3  33.6±8.3       ns 
Bilirubin, mg/dL     0.80±0.04  0.88±0.07     ns 
Uric Acid mg/dL     6.70±0.17 7.84±0.43 <0.05 
Glucose, mg/dL     114.9±3.1  115.2±4.3 ns 
Total Cholesterol, mg/dL    169.0±3.2  170.8±5.8  ns 
HDL Cholesterol, mg/dL    40.9±0.8  40.1±1 .7 ns 
LDL Cholesterol, mg/dL    103.1±2.6  103.8±5.3        ns 
Triglycerides, mg/dL     127.3±5.1  133.8±12.0      ns 
C Reactive Protein mg/dL    0.73±0.16 1.34±0.64 <0.01 
Thyrotropin, mUI/L     3.4±0.7 2.3±0.3           ns 
Thyroxine, ng/dL     1.29±0.02  1.35±0.06       ns 
Hemoglobin, g/L     138.3±1.2 131.5±2.8      <0.05 
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Hematocrit, L/L      0.423±0.003 0.407±0.008 <0.05 
Erythrocyte count, 10E12/L    4.64±0.04 4.35±0.10 =0.001 
Lymphocytes count, 10E9/L    1.9±0.05 1.6±0.08 <0.05 
Platelet count, 10E9/L    222.3±5.4 205.0±8.2 ns 
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Table 4. Pharmacological treatment of HF patients stratified by sAXL levels.  
______________________________________________________________________ 
           sAXL, ng/mL 
      ___________________________________ 
Pharmacological treatment    <98.1  ≥98.1  P 
No of patients          144  48 
______________________________________________________________________ 
ACEI, n (%)      91 (66) 34 (71) ns  
ARB, n (%)      36 (27) 7 (15)  ns 
ACEI and/or ARB, n (%)      127 (91) 41 (85) ns 
Beta-blocker, n (%)      132 (94) 44 (92) ns 
Ca-antagonists, n (%)      12 (9)  3 (6)  ns 
Antithrombotic and/or anticoagulant, n (%)  110 (80) 41 (85) ns 
Statins, n (%)      95 (69) 21 (44) <0.01 
Antidiabetics, n (%)      41 (30) 11 (23) ns 
Diuretics, n (%)      104 (75) 42 (88) 0.055 
Antialdosteronic agents, n (%)     74 (54) 28 (58) ns  
Digoxin, n (%)      12 (9)  9 (19)  0.054 
Antiarrhythmics, n (%)      26 (19) 15 (31) 0.054  
Nitrates, n (%)      17 (12) 8 (17)  ns 
Hydralazine, n (%)      5 (4)  3 (6)  ns 
Anemia treatment, n (%)      6 (4)  2 (4)  ns 
______________________________________________________________________ 
ACEI (Angiotensin Converting Enzyme Inhibitor), ARB (Angiotensin Receptor 
Blocker).  
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Legends 
Figure 1.Western Blot analysis of AXL and ADAM10 expression in myocardial 
biopsies. A, representative western blot of myocardial biopsies from 2 healthy (control) 
and 5 pathological (heart failure) left ventricle samples. Thirty μg of protein were 
loaded in each lane. AXL (upper panel) appears as a doublet of 140-160 kDa bands, 
while ADAM10 (lower panel) appears as a … kDa and ….kDa bands. Quantification of 
the 140 and 160 kDa AXL bands (B) and … kDa and ….kDa ADAM10 bands (C) by 
densitometry of 3 different blots with control (n=11) and heart failure (n=15) samples. 
Results were compared with a T-test (****P<0.0001). 
Figure 2. Serum sAXL values from controls and HF patients. A, Boxplot of serum 
sAXL from controls (C) and heart failure (HF) patients. B, sAXL serum levels from HF 
patients belonging to NYHA functional class 2 (II) or 3-4 (III-IV). Ln-sAXL between 
groups was compared with a T-test (****P<0.0001). 
Figure 3.  Serum sAXL levels from HF patients with different HF etiologies. Boxplot 
of serum sAXL from HF patients divided in 5 different groups according to their 
etiology; idiopathic (idiop), ischemic (isch), valvular (valv), hypertensive (hypert) and 
others.  
Figure 4.  Kaplan-Meier survival curve from HF patients divided according their sAXL 
and BNP levels and considering the major HF events (all-cause mortality, 
transplantation and HF hospitalizations). A, Kaplan-Meier survival curve from patients 
with sAXL below (L_sAXL, dotted grey line) or above the 3
rd
 quartile cut-off point 
(98.1 ng/mL, H_sAXL dotted black line). The differences in HF evolution were 
compared with the Cox Regression model (***P<0.001). B, Kaplan-Meier survival 
curve from patients with BNP below (L_BNP, dotted grey line) or above the 3
rd
 quartile 
cut-off point (362.7 pg/mL, H_BNP dotted black line, ****P<0.0001). Kaplan-Meier 
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survival curve from patients with the 2 markers, sAXL and BNP, levels above the 3
rd
 
quartiles cut-off points (H_sAXL+BNP black solid line) or with one or both values 
below the 3
rd
 quartiles cut-off points (L_sAXL+BNP grey solid line, ****P<0.0001). * 
P<0.05 between H_BNP and H_sAXL+BNP 
 
 
